Respimat from Boehringer Ingelheim is now the first and only inhaler to be awarded the Ease of Use Commendation by the Arthritis Foundation. This award identifies products that make life easier for ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...

Boehringer Ingelheim’s Respimat Inhaler, designed for those with arthritis, has received the Arthritis Foundation Ease of Use Commendation. The commendation is awarded to “products proven to make life ...

Two different doses of the drug were studied among those who used the new Respimat inhaler. "Our study found that the safety profile of tiotropium delivered with the Respimat system, in either a dose ...

A few months after the FDA cleared digital health company Propeller Health’ first collaboration with Boehringer Ingelheim to use its remote monitoring platform with BI’s Respimat inhaler, the FDA has ...

Propeller Health announced that the FDA has given clearance to market its Propeller platform for use with drugs using the Diskus dry powder inhaler device for asthma and COPD, and clearance for use ...

RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...